Multiple myeloma (MM) is one of the most common malignant plasma cell diseases, accounting for 10% of hematopoietic malignancies. It is characterized by malignant proliferation of monoclonal plasma cells and secretion of a large number of monoclonal immunoglobulins, causing a series of clinical changes such as bone pain, pathological fracture, hematopoietic abnormalities, monoclonal globulinemia and impaired renal function. The current general MM diagnostic criteria are mainly standard WHO (2001) and International MM Working Group (2003). This disease is easily misdiagnosed and the rate of misdiagnosis is as high as 60%. Clinical studies have found that the development of MM is accompanied by changes in the number or structure of related genes at various specific cytogenetic levels. For example, chromosome 13 occurs in 85% of MM patients.
13q14/13q34 is a dual-color hybrid probe. The orange-red fluorescent dye directly labels the D13S319 probe and specifically detects the D13S319 gene at 13q14.2. The green fluorescent dye directly labels the 13q34 probe, which specifically detects LAMP1 gene at the 13q34 region.
Clinical studies have found that the occurrence and development of MM is accompanied by a variety of specific changes in the number or structure of related genes at the cytogenetic level. Chromosome 13 haplotypes occur in 85% of patients with MM, and adverse prognostic factor found.
Product size: 100μL FISH probe ( ⬤ | ⬤ ) + Pretreatment reagent (10 tests) + Antifade staining solution DAPI (10 tests).